Abstract:Background Bladder cancer is a malignant tumor in the urinary system with high mortality and recurrence rates. However, the causes and recurrence mechanism of bladder cancer are not fully understood. In this study, we used integrated bioinformatics to screen for key genes associated with the development of bladder cancer and reveal their potential molecular mechanisms. Methods The GSE7476 , GSE13507 , GSE37815 and GSE65635 expression profiles were downloaded from the Gene Expression Omnibus database, and these datasets contain 304 tissue samples, including 81 normal bladder tissue samples and 223 bladder cancer samples. The RobustRankAggreg (RRA) method was utilized to integrate and analyze the four datasets to obtain integrated differentially expressed genes (DEGs), and the gene ontology (GO) functional annotation and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis were performed. Protein-protein interaction (PPI) network and module analyses were performed using Cytoscape software. The OncoLnc online tool was utilized to analyze the relationship between the expression of hub genes and the prognosis of bladder cancer. Results In total, 343 DEGs, including 111 upregulated and 232 downregulated genes, were identified from the four datasets. GO analysis showed that the upregulated genes were mainly involved in mitotic nuclear division, the spindle and protein binding. The downregulated genes were mainly involved in cell adhesion, extracellular exosomes and calcium ion binding. The top five enriched pathways obtained in the KEGG pathway analysis were focal adhesion (FA), PI3K-Akt signaling pathway, proteoglycans in cancer, extracellular matrix (ECM)-receptor interaction and vascular smooth muscle contraction. The top 10 hub genes identified from the PPI network were vascular endothelial growth factor A (VEGFA), TOP2A, CCNB1, Cell division cycle 20 (CDC20), aurora kinase B, ACTA2, Aurora kinase A, UBE2C, CEP55 and CCNB2. Survival analysis revealed that the expression levels of ACTA2, CCNB1, CDC20 and VEGFA were related to the prognosis of patients with bladder cancer. In addition, a KEGG pathway analysis of the top 2 modules identified from the PPI network revealed that Module 1 mainly involved the cell cycle and oocyte meiosis, while the analysis in Module 2 mainly involved the complement and coagulation cascades, vascular smooth muscle contraction and FA. Conclusions This study identified key genes and pathways in bladder cancer, which will improve our understanding of the molecular mechanisms underlying the development and progression of bladder cancer. These key genes might be potential therapeutic targets and biomarkers for the treatment of bladder cancer.

Identification of cancer-keeping genes as therapeutic targets by finding network control hubs

Cancer-keeper Genes As Therapeutic Targets.

Identifying Hepatocellular Carcinoma Driver Genes by Integrative Pathway Crosstalk and Protein Interaction Network

Identification and verification of hub genes associated with the progression of non-small cell lung cancer by integrated analysis

Identification of druggable hub genes and key pathways associated with cervical cancer by protein-protein interaction analysis: An in silico study

Identification of Hub Genes Associated with Progression and Prognosis of Bladder Cancer by Integrated Bioinformatics Analysis.

CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer Therapy

Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data

Identification of key candidate genes and biological pathways in bladder cancer

Identification of Hub Genes in Bladder Cancer Based on Weighted Gene Co‐expression Network Analysis from TCGA Database

Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer

Identification of Hub Genes and Pathways Associated with Bladder Cancer Based on Co-Expression Network Analysis

Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma

Survival-based Bioinformatics Analysis to Identify Hub Genes and Key Pathways in Non-Small Cell Lung Cancer

Network control principles for identifying personalized driver genes in cancer

Identification and validation of key genes with prognostic value in non‐small‐cell lung cancer via integrated bioinformatics analysis

Identification of Hub Genes Associated with Progression and Prognosis in Patients with Bladder Cancer

Explore Key Genes and Mechanisms Involved in Colon Cancer Progression Based on Bioinformatics Analysis

Identifying Cancer Driver Lncrnas Bridged by Functional Effectors Through Integrating Multi-omics Data in Human Cancers

Identification of cancer-related gene network in hepatocellular carcinoma by combined bioinformatic approach and experimental validation.

Identifification of Key Genes Involved in Colorectal Cancer: A Bioinformatics Analysis